The treatment of<unk>  remains challenging due to the lack of clinical trials investigating the disease as its own clinical entity. It is often grouped with MDS in clinical trials, and for this reason the treatment of<unk>  is very similar to that of MDS. Most cases are dealt with as supportive rather than curative because most therapies do not effectively increase survival. Indications for treatment include the presence of B symptoms, symptomatic organ involvement, increasing blood counts, hyperleukocytosis, leukostasis and/or worsening cytopenias. Blood transfusions and erythropoietin administration are used to raise haemoglobin levels in cases with anemia. Azacitidine is a drug approved by the U.S. Food and Drug Administration (FDA) for the treatment of<unk>  and by the European Medicines Agency (EMA) for high risk non-proliferative<unk>  with 10–19% marrow blasts. It is a cytidine analogue that causes hypomethylation of DNA by inhibition of DNA methyltransferase. Decitabine is a similar drug to azacitidine and is approved by the FDA for treatments of all subtypes of MDS, including<unk> . Hydroxyurea is a chemotherapy that is used in the myeloproliferative form of<unk>  to reduce cell numbers. Decitabine/cedazuridine (Inqovi) is a fixed-dosed combination medication for the treatment of adults with myelodysplastic syndromes (MDS) and<unk>  <unk>  that was approved for use in the United States in July 2020. Haematopoietic stem cell transplant remains the only curative treatment for<unk> . However, due to the late age of onset and presence of other illnesses, this form of treatment is often not possible.
Chronic myelomonocytic leukemia
Prolymphocytic leukemia
Large granular lymphocytic leukemia
Chronic neutrophilic leukemia
Acute myelomonocytic leukemia
Mixed-phenotype acute leukemia
Atypical chronic myeloid leukemia
Acute myeloblastic leukemia with maturation